Definium Therapeutics, Inc. filed a current report on Form 8-K on September 8, 2026, disclosing that the U.S. Food and Drug Administration granted breakthrough designation to its DT120 ODT program for the treatment of major depressive disorder.
Australia's government unveiled legislation Tuesday that would let social media users switch off algorithm-driven feeds, the latest step by regulators worldwide to curb the influence of major technology platforms. The proposed “My Feed, My Way” initiative would require platforms to let users over the …
Novartis shares fell sharply Tuesday after the pharmaceutical company said its del-desiran drug for a muscle-wasting disorder failed in a late-stage trial, marking its third clinical setback within a week and putting the stock on track for its worst trading day since March 2020. …
The US Treasury Department sanctioned 27 Iranian airlines and a handful of other entities Tuesday, extending its ongoing campaign to isolate Iran's economy as the country and its regional allies continue to launch attacks around the Strait of Hormuz. The action targets all Iranian …
Global maritime authorities warned Tuesday that the emergence of “parallel systems” threatens to create a two-tier structure in international shipping that undermines trust and safety at sea. In a joint statement, the Consultative Shipping Group, an informal cooperation between the maritime authorities of 18 …
Mistral said Tuesday it raised 3 billion euros, roughly $3.5 billion, in fresh funding led by Samsung, as the French startup positions itself as a European alternative to rivals including OpenAI and Anthropic. The round also involved the Scaleup Europe Fund, a European Union-backedInvestmentvehicle …
Novartis' failure in a closely watched cardiovascular trial has raised questions over one of the pharmaceutical industry's biggest drug races and rival treatments from Amgen and Eli Lilly. The pelacarsen drug, developed jointly with Ionis Pharmaceuticals, reduced a particularly harmful form of cholesterol known …
Spyre Therapeutics, Inc. filed a Form 8-K on September 8, 2026, disclosing 12-week induction topline data from Part A of its Phase 2 SKYLINE trial evaluating SPY003 in moderately-to-severely active ulcerative colitis.
Relmada Therapeutics, Inc. filed a Form 8-K on September 8, 2026, disclosing that Dr. Raj S. Pruthi's employment as Chief Medical Officer - Urology ended on September 3, 2026.
DPC Holdings PLC filed a Form 8-K with the SEC on September 8, 2026, disclosing that on September 3, 2026, the company and certain subsidiaries entered into a new $325 million senior unsecured revolving credit facility with Barclays Bank PLC as administrative agent, while …